Q3 2025 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Reduced by HC Wainwright

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at HC Wainwright cut their Q3 2025 EPS estimates for Axsome Therapeutics in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.47 for the quarter, down from their previous forecast of $0.51. HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at $1.33 EPS.

A number of other equities research analysts also recently issued reports on the stock. Guggenheim increased their target price on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. UBS Group started coverage on Axsome Therapeutics in a research note on Tuesday, February 6th. They issued a “buy” rating and a $111.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and set a $150.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, April 10th. Finally, Morgan Stanley upgraded shares of Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $90.00 to $115.00 in a report on Monday, April 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $121.92.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $75.68 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.63 and a quick ratio of 3.52. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -14.55 and a beta of 1.13. The business’s 50-day moving average is $73.99 and its 200-day moving average is $75.73. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.48. The business had revenue of $71.53 million for the quarter, compared to the consensus estimate of $70.38 million. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Trexquant Investment LP bought a new position in shares of Axsome Therapeutics during the third quarter worth $1,220,000. Kennedy Capital Management LLC grew its stake in Axsome Therapeutics by 24.2% in the third quarter. Kennedy Capital Management LLC now owns 12,092 shares of the company’s stock valued at $845,000 after acquiring an additional 2,354 shares during the period. Wellington Management Group LLP increased its holdings in shares of Axsome Therapeutics by 18.9% in the third quarter. Wellington Management Group LLP now owns 237,554 shares of the company’s stock worth $16,603,000 after acquiring an additional 37,843 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Axsome Therapeutics by 403.8% during the third quarter. Victory Capital Management Inc. now owns 18,934 shares of the company’s stock worth $1,323,000 after purchasing an additional 15,176 shares during the period. Finally, Phocas Financial Corp. acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at approximately $2,140,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Mark L. Jacobson sold 24,662 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Roger Jeffs sold 29,976 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares of the company’s stock, valued at $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is currently owned by insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.